Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 19, 2024Journal of Clinical Oncology

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

Hagop M. Kantarjian
Hagop M. KantarjianThe University of Texas MD Anderson Cancer CenterNSNicholas J. ShortThe University of Texas MD Anderson Cancer CenterFHFadi HaddadTrinity Health

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kantarjian et al. (2024) studied this question.

synapsesocial.com/papers/68e5fa6bb6db64358758eecahttps://doi.org/10.1200/jco.24.00272
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial2021 · 206 citations
  2. 2Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results2023 · 105 citations
  3. 3Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology2017 · 142 citations
  4. 4P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL2022 · 17 citations
  5. 5A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias2013 · 1,147 citations